Exicure Inc (XCUR)

NASDAQ
1.3300
-0.0800(-5.67%)
After Hours
1.3600
+0.0300(+2.2556%)
- Real-time Data
  • Volume:
    170,906
  • Bid/Ask:
    1.3300/1.3600
  • Day's Range:
    1.3300 - 1.3900

XCUR Overview

Prev. Close
1.41
Day's Range
1.33-1.39
Revenue
3.66M
Open
1.37
52 wk Range
1.09-2.83
EPS
-0.55
Volume
170,906
Market Cap
124.23M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,468,580
P/E Ratio
-
Beta
1.3
1-Year Change
-31.22%
Shares Outstanding
88,108,543
Next Earnings Date
Nov 11, 2021
What is your sentiment on Exicure Inc?
or
Market is currently closed. Voting is open during market hours.

Exicure Inc News

Exicure Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellNeutralStrong Sell
SummaryStrong SellStrong SellStrong SellSellStrong Sell

Exicure Inc Company Profile

Exicure Inc Company Profile

Employees
78

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich’s ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington’s disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.

Read More
  • who need coins I sale
    0
    • hi
      0
      • $20m upfront payment + Royalties + fixed fees = Boom
        0
        • 2-3$ then dump
          0
          • I like this one, all of the biotechs that treat inflammation have gone crazy. Chart showing some accumulation.
            0
            • $2.92 close today.
              0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.